Proteasome inhibition decreases cardiac remodeling after initiation of pressure overload
- 1 October 2008
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 295 (4) , H1385-H1393
Abstract
We tested the possibility that proteasome inhibition may reverse preexisting cardiac hypertrophy and improve remodeling upon pressure overload. Mice were submitted to aortic banding and followed up for 3 wk. The proteasome inhibitor epoxomicin (0.5 mg/kg) or the vehicle was injected daily, starting 2 wk after banding. At the end of the third week, vehicle-treated banded animals showed significant (P < 0.05) increase in proteasome activity (PA), left ventricle-to-tibial length ratio (LV/TL), myocyte cross-sectional area (MCA), and myocyte apoptosis compared with sham-operated animals and developed signs of heart failure, including increased lung weight-to-TL ratio and decreased ejection fraction. When compared with that group, banded mice treated with epoxomicin showed no increase in PA, a lower LV/TL and MCA, reduced apoptosis, stabilized ejection fraction, and no signs of heart failure. Because overload-mediated cardiac remodeling largely depends on the activation of the proteasome-regulated transcription factor NF-κB, we tested whether epoxomicin would prevent this activation. NF-κB activity increased significantly upon overload, which was suppressed by epoxomicin. The expression of NF-κB-dependent transcripts, encoding collagen types I and III and the matrix metalloprotease-2, increased (P < 0.05) after banding, which was abolished by epoxomicin. The accumulation of collagen after overload, as measured by histology, was 75% lower (P < 0.05) with epoxomicin compared with vehicle. Myocyte apoptosis increased by fourfold in hearts submitted to aortic banding compared with sham-operated hearts, which was reduced by half upon epoxomicin treatment. Therefore, we propose that proteasome inhibition after the onset of pressure overload rescues ventricular remodeling by stabilizing cardiac function, suppressing further progression of hypertrophy, repressing collagen accumulation, and reducing myocyte apoptosis.Keywords
This publication has 54 references indexed in Scilit:
- Suppression of Cardiomyocyte Hypertrophy by Inhibition of the Ubiquitin-Proteasome SystemHypertension, 2008
- Optimal determination of heart tissue 26S-proteasome activity requires maximal stimulating ATP concentrationsJournal of Molecular and Cellular Cardiology, 2007
- The ubiquitin-proteasome system in cardiac physiology and pathologyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Targeted Deletion of Matrix Metalloproteinase 2 Ameliorates Myocardial Remodeling in Mice With Chronic Pressure OverloadHypertension, 2006
- Protein turnover in cardiac cell growth and survivalCardiovascular Research, 2005
- Endoplasmic reticulum stress: cell life and death decisionsJournal of Clinical Investigation, 2005
- Proteasome inhibition protects HT22 neuronal cells from oxidative glutamate toxicityJournal of Neurochemistry, 2005
- Long‐term up‐regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathwayThe FASEB Journal, 2004
- Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in MiceCirculation, 2003
- Involvement of Nuclear Factor-κB and Apoptosis Signal-Regulating Kinase 1 in G-Protein–Coupled Receptor Agonist–Induced Cardiomyocyte HypertrophyCirculation, 2002